跳至主要内容

Gain Client Recognition Again! Medicilon won the 2023 SicaGene "Best Partner Award"

 Recently, Shanghai Medicilon Inc. (Medicilon) won the "Best Partner Award" from SicaGene.  The strong support provided in collaboration projects has been recognized by client again.

SicaGene.webp

Medicilon and SicaGene: Go Deep Alone, Go Far Together

The collaboration stems from a shared vision in the field of nucleic acid drugs.  Antisense oligonucleotide drugs can break through the "undruggable targets" limitations of traditional small molecule drugs, but they also have extremely high technical barriers and development difficulties.  As one of the first China innovative pharmaceutical companies to enter the ASO field, SicaGene has independently developed and constructed core technology platforms such as  SicaScreenTM、SicaChemistryTM、SicaDeliveryTM , focusing on drug development in the fields of cardiovascular disease, viruses, and ophthalmology.  SicaGene has also achieved efficient development of ASO drugs with high activity, low dosage, long administration cycle, good clinical tolerance and controllable cost.

It is also Medicilon's vision to improve the druggability and R&D efficiency of nucleic acid drugs and help nucleic acid drugs benefit the world.  To this end, Medicilon relies on the Nucleic Acid Drug R&D Service Platform to empower SicaGene's ASO drug research and development, and the trust and support from SicaGene also encourage Medicilon to continue to innovate and improve.  Through close collaboration between the two parties, the collaboration has achieved positive progress and phased results.

Nucleic Acid Drug R&D Service Platform provides one-stop support for R&D

Medicilon's Nucleic Acid Drug R&D Service Platform is an integrated and comprehensive platform that integrates drug discovery, production and preclinical research.  Based on a rigorous scientific attitude, an open technology platform and advanced instruments and equipment, Medicilon can provide nucleic acid drug discovery, screening and preclinical research services to pharmaceutical companies and scientific research institutions.

Medicilon will continue to target cutting-edge tracks such as nucleic acid, cell and gene therapy, PROTAC, and ADC, strengthen technological innovation, and gather superior resources to provide clients with a one-stop biopharmaceutical preclinical R&D service platform and to empower global partners to accelerate pharmaceutical innovation.

标签：

评论

发表评论

此博客中的热门博文

The Launch Meeting was Held by Medicilon and DAC Biotech of the Contract Research on ADC Preclinical Study

  Chuansha, Shanghai, Nov. 8th, 2019 — Medicilon held the launch meeting with Hangzhou DAC Biotech Co., Ltd to initiate the   preclinical study   of the antibody-drug-conjugate (ADC)  DXC005, including the   pharmacology study ,   DMPK study   and the   safety evaluation . Medicilon has previously completed integrated  preclinical research  on ADC drugs cooperating with DAC Biotech and other companies. Two of them has been approved by NMPA and entered Phase I clinical trials. About Hangzhou DAC Biotech Co., Ltd Hangzhou DAC Biotech, Co., Ltd was officially registered in HEDA Area, Hangzhou City, Zhejiang Province, China around the end of Year 2012, and is located nearby the bank of beautiful Qiantang River. The company focuses on developing conjugate of monoclonal antibody and small molecular cytotoxic drug, both of which are banded together with smart linkers. About Antibody-Drug-Conjugate (ADC) ADCs ...
发表评论
阅读全文

Medicilon assisted Hangzhou DAC Biotech in approval of clinical study of ADC drug DAC-002

  On July 20, 2020, DAC Biotech’s new   ADC drug development , TROP2-ADC—DAC-002 was approved of clinical study by NMPA. for the indication of solid malignant tumor. Medicilon completed   preclinical pharmacokinetic  and toxicological studies in this project, accelerating the development process. DAC-002 is an ADC anti-Trop2 monoclonal antibody conjugated by an intelligent ligand against Tubulysin B analogue. It is used to treat Trop2 triple negative breast cancer, small cell lung cancer, non-small cell lung cancer and pancreatic cancer.Trop2 can promote the proliferation, invasion, metastasis and diffusion of tumor cells, and its high expression is closely related to the shortening of survival time and poor prognosis of tumor patients. Therefore, it is of great significance to study anti-tumor drugs targeted by Trop2. Reference: Medicilon Assists - The first China-made targeting folic acid receptor FRα ADC injection BAT8006 was approved for clinical use Medicilon As...
发表评论
阅读全文

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

  On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration.  The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages      Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies,  ADCs ,  mRNA vaccines ,  small nucleic acid drugs ,  PROTAC , and  CGT technical service platform  that have helped 421 INDs obtain clinical approval.  It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...
发表评论
阅读全文